NASD · Healthcare · Biotechnology · Australia
Telix Pharmaceuticals Ltd ADR is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Telix Pharmaceuticals Ltd ADR stock.
Overvalued: intrinsic value $2.57 per share, market price $9.10, margin of safety -254.4% (as of 2026-10-30).
Discounting its cash flows at 11.0% (average of 2 methods) values the shares at $2.57; the price of $9.10 is 254% above that value.
74 more in this industry show a wider margin of safety.
TLX is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 11.0% (average of 2 methods) values the shares at $2.57; the price of $9.10 is 254% above that value.
$2.57 per share (as of the 2026-10-30 close), against a market price of $9.10. That is a margin of safety of -254.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.